Novo Nordisk

Rigel in-licensed exclusive, worldwide rights to develop, manufacture, and commercialize olutasidenib, an oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor, in all indications, including relapsed/refractory acute myeloid leukemia and other malignancies.

Under the terms of the agreement, Forma (now Novo Nordisk) received an upfront payment and is eligible to receive additional near-term regulatory, approval, commercial sale milestones, and tiered royalties on sales.

Rigel is responsible for the commercialization of olutasidenib in the U.S., and intends to work with partners to further develop and commercialize olutasidenib outside the U.S.